A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age21+
SponsorMBQ Pharma
About this trial
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Eligibility criteria
Qualifiers
The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.
Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.
Participants with known brain metastases may be eligible if specific conditions are met.
Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.
Disqualifiers
The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.
Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.
Females who are pregnant or breastfeeding.
Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
Trial design
Treatments tested in this trial
- MBQ-167
Treatment groups
48 Participants
are divided into 1 treatment groupSponsors and collaborators
MBQ Pharma
Lead sponsor
Congressionally Directed Medical Research Programs
Collaborator
Source ClinicalTrials.gov